Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Green Website

Jeffrey E. Green, M.D.

Selected Publications

1)  Chu IM, Lai WC, Aprelikova O, El Touny LH, Kouros-Mehr H, Green JE.
Expression of GATA3 in MDA-MB-231 triple-negative breast cancer cells induces a growth inhibitory response to TGFß.
PLoS ONE. 8: e61125, 2013.
2)  Hu Y, Bai L, Geiger T, Goldberger N, Walker RC, Green JE, Wakefield LM, Hunter KW.
Genetic Background May Contribute to PAM50 Gene Expression Breast Cancer Subtype Assignments.
PLoS ONE. 8: e72287, 2013.
3)  Ahn SG, Dong SM, Oshima A, Kim WH, Lee HM, Lee SA, Kwon SH, Lee JH, Lee JM, Jeong J, Lee HD, Green JE.
LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients.
Breast Cancer Res. Treat. 141: 89-99, 2013.
4)  Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, Aprelikova O, Shou J, Piwinica-Worms H, Caplen NJ, Hollingshead MG, Green JE.
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Breast Cancer Res. 14: R109, 2012.
5)  Chu IM, Michalowski AM, Hoenerhoff M, Szauter KM, Luger D, Sato M, Flanders K, Oshima A, Csiszar K, Green JE.
GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells.
Oncogene. 31: 2017-27, 2012.
6)  Paolicchi E, Crea F, Farrar WL, Green JE, Danesi R.
Histone lysine demethylases in breast cancer.
Crit. Rev. Oncol. Hematol. [Epub ahead of print], 2012.
7)  Aprelikova O, Green JE.
MicroRNA regulation in cancer-associated fibroblasts.
Cancer Immunol. Immunother. 61: 231-7, 2012.
8)  Switzer CH, Glynn SA, Cheng RY, Ridnour LA, Green JE, Ambs S, Wink DA.
S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer.
Mol. Cancer Res. 10: 1203-15, 2012.
9)  Hudson TS, Carlson BA, Hoeneroff MJ, Young HA, Sordillo L, Muller WJ, Hatfield DL, Green JE.
Selenoproteins reduce susceptibility to DMBA-induced mammary carcinogenesis.
Carcinogenesis. 33: 1-6, 2012.
10)  Rodriguez V, Vasudevan S, Noma A, Carlson BA, Green JE, Suzuki T, Chandrasekharappa SC.
Structure-Function Analysis of Human TYW2 Enzyme Required for the Biosynthesis of a Highly Modified Wybutosine (yW) Base in Phenylalanine-tRNA.
PLoS ONE. 7: e39297, 2012.
11)  Green J, Ried T, eds.
Genetically-engineered Mice for Cancer Research: design, analysis, pathways, validation and pre-clinical testing.
NY: Springer; 2011. [Book (Editor)]
12)  Zhu M, Michalowski A, Green J.
Green J, Ried T, eds.
Expression Profiling of Mouse Models of Human Cancer: model categorization and guidance for preclinical testing. In: Genetically-engineered Mice for Cancer Research: design, analysis, pathways, validation and pre-clinical testing.
New York: Springer; 2011. p. 209-234 [Book Chapter]
13)  Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Michalowski A, Green JE.
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
PLoS ONE. 6: e16694, 2011.
14)  Barkan D, Green JE.
An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth.
J Vis Exp. 2011.
15)  Murphy EA, Davis JM, Barrilleaux TL, McClellan JL, Steiner JL, Carmichael MD, Pena MM, Hebert JR, Green JE.
Benefits of exercise training on breast cancer progression and inflammation in C3(1)SV40Tag mice.
Cytokine. 274-279, 2011.
16)  Hoenerhoff M, Chu IM, Green JE.
BMI1 suffers a degrading experience.
Cell cycle (Georgetown, Tex.). 10, 2011.
17)  Kim HK, Kim J, Korolevich S, Choi IJ, Kim CH, Munroe DJ, Green JE.
Distinctions in gastric cancer gene expression signatures derived from laser capture microdissection versus histologic macrodissection.
BMC medical genomics. 4: 48, 2011.
18)  Zhu M, Yi M, Kim CH, Deng C, Li Y, Medina D, Stephen R, Green JE.
Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage.
Genome biology. 12: R77, 2011.
19)  Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, Choi IJ, Munroe DJ, Green JE.
miRNA signature associated with outcome of gastric cancer patients following chemotherapy.
BMC Med Genomics. 4: 79, 2011.
20)  Reindl W, Bowen BP, Balamotis MA, Green JE, Northen TR.
Multivariate analysis of a 3D mass spectral image for examining tissue heterogeneity.
Integr Biol (Camb). 3: 460-7, 2011.
21)  O'Brien J, Hansen K, Barkan D, Green J, Schedin P.
NSAIDs target pro-tumorigenic extracellular matrix of the postpartum mammary gland.
International Journal of Developmental Biology. 745-755, 2011.
22)  Das S, Bosley AD, Ye X, Chan KC, Chu I, Green JE, Issaq HJ, Veenstra TD, Andresson T.
Comparison of strong cation exchange and SDS-PAGE fractionation for analysis of multiprotein complexes.
J. Proteome Res. 9: 6696-704, 2010.
23)  Barkan D, Green JE, Chambers AF.
Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth.
Eur. J. Cancer. 46: 1181-8, 2010.
24)  Kim HK, Reyzer ML, Choi IJ, Kim CG, Kim HS, Oshima A, Chertov O, Colantonio S, Fisher RJ, Allen JL, Caprioli RM, Green JE.
Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry.
J. Proteome Res. 9: 4123-30, 2010.
25)  Liu B, Liu L, Tsykin A, Goodall GJ, Green JE, Zhu M, Kim CH, Li J.
Identifying functional miRNA-mRNA regulatory modules with correspondence latent dirichlet allocation.
Bioinformatics. 26: 3105-11, 2010.
26)  Barkan D, El Touny LH, Michalowski AM, Smith JA, Chu I, Davis AS, Webster JD, Hoover S, Simpson RM, Gauldie J, Green JE.
Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment.
Cancer Res. 70: 5706-16, 2010.
27)  Mendoza A, Hong SH, Osborne T, Khan MA, Campbell K, Briggs J, Eleswarapu A, Buquo L, Ren L, Hewitt SM, Dakir el-H, Garfield S, Walker R, Merlino G, Green JE, Hunter KW, Wakefield LM, Khanna C.
Modeling metastasis biology and therapy in real time in the mouse lung.
J. Clin. Invest. 120: 2979-88, 2010.
28)  Calvo A, Perez-Stable C, Segura V, Catena R, Guruceaga E, Nguewa P, Blanco D, Parada L, Reiner T, Green JE.
Molecular characterization of the Ggamma-globin-Tag transgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer.
Prostate. 70: 630-45, 2010.
29)  Hoenerhoff MJ, Shibata MA, Bode A, Green JE.
Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer.
Transgenic research. 2010.
30)  Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Yamada Y, Arao T, Nishio K, Michalowski A, Green JE.
Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.
The pharmacogenomics journal. 2010.
31)  Hoenerhoff MJ, Chu I, Barkan D, Liu ZY, Datta S, Dimri GP, Green JE.
BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases.
Oncogene. 2009.
32)  Bennett C, Green J.
Genomic Analyses as a Guide to Target Identification and Pre-clinical Testing of Mouse Models of Breast Cancer.
Toxicologic Pathology. 38: 88-95, 2009.
33)  Gonzalez-Moreno O, Lecanda J, Green JE, Segura V, Catena R, Serrano D, Calvo A.
VEGF elicits Epithelial-to-Mesenchymal Transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop.
Experimental cell research. 2009.
34)  Hoenerhoff M, Michalowska A, Qiu T, Green JE.
Gavin G, eds.
A Bioinformatics Approach to the Analysis of Animal Models of Cancer. In: Bioinformatics in Cancer and Cancer Therapy.
Totowa: Humana; 2008. p. 55-76 [Book Chapter]
35)  Joshi BH, Leland P, Calvo A, Green JE, Puri RK.
Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy.
Cancer Res. 68: 9311-7, 2008.
36)  Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JM.
Identification of tumor-initiating cells in a p53-null mouse model of breast cancer.
Cancer Res. 68: 4674-82, 2008.
37)  Calvo A, Catena R, Noble MS, Carbott D, Gil-Bazo I, Gonzalez-Moreno O, Huh JI, Sharp R, Qiu TH, Anver MR, Merlino G, Dickson RB, Johnson MD, Green JE.
Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis.
Oncogene. 2008.
38)  Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, Hoenorhoff MJ, Liu ZY, Costes SV, Cho EH, Lockett S, Khanna C, Chambers AF, Green JE.
Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton.
Cancer Res. 68: 6241-50, 2008.
39)  Ohta S, Lai EW, Morris JC, Pang AL, Watanabe M, Yazawa H, Zhang R, Green JE, Chan WY, Sirajuddin P, Taniguchi S, Powers JF, Tischler AS, Pacak K.
Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse pheochromocytoma cells.
Mol. Carcinog. 47: 245-51, 2008.
40)  Abate-Shen C, Brown PH, Colburn NH, Gerner EW, Green JE, Lipkin M, Nelson WG, Threadgill D.
The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges.
Cancer prevention research (Philadelphia, Pa.). 1: 161-6, 2008.
41)  Bennett CN, Green JE.
Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models.
Breast Cancer Res. 10: 213, 2008.
42)  Huh JI, Qiu TH, Chandramouli GV, Charles R, Wiench M, Hager GL, Catena R, Calvo A, LaVallee TM, Desprez PY, Green JE.
2-methoxyestradiol induces mammary gland differentiation through amphiregulin-epithelial growth factor receptor-mediated signaling: molecular distinctions from the mammary gland of pregnant mice.
Endocrinology. 148: 1266-77, 2007.
43)  Varticovski L, Hollingshead MG, Robles AI, Wu X, Cherry J, Munroe DJ, Lukes L, Anver MR, Carter JP, Borgel SD, Stotler H, Bonomi CA, Nunez NP, Hursting SD, Qiao W, Deng CX, Green JE, Hunter KW, Merlino G, Steeg PS, Wakefield LM, Barrett JC.
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models.
Clin. Cancer Res. 13: 2168-77, 2007.
44)  Datta S, Hoenerhoff MJ, Bommi P, Sainger R, Guo WJ, Dimri M, Band H, Band V, Green JE, Dimri GP.
Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways.
Cancer Res. 67: 10286-95, 2007.
45)  Shoushtari AN, Michalowska AM, Green JE.
Comparing genetically engineered mouse mammary cancer models with human breast cancer by expression profiling.
Breast disease. 28: 39-51, 2007.
46)  Deeb KK, Michalowska AM, Yoon CY, Krummey SM, Hoenerhoff MJ, Kavanaugh C, Li MC, Demayo FJ, Linnoila I, Deng CX, Lee EY, Medina D, Shih JH, Green JE.
Identification of an Integrated SV40 T/t-Antigen Cancer Signature in Aggressive Human Breast, Prostate, and Lung Carcinomas with Poor Prognosis.
Cancer Res. 67: 8065-8080, 2007.
47)  Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM.
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.
Genome Biol. 8: R76, 2007.
48)  Catena R, Muniz-Medina V, Moralejo B, Javierre B, Best CJ, Emmert-Buck MR, Green JE, Baker CC, Calvo A.
Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis.
Int. J. Cancer. 120: 2096-109, 2007.
49)  Hudson TS, Hartle DK, Hursting SD, Nunez NP, Wang TT, Young HA, Arany P, Green JE.
Inhibition of Prostate Cancer Growth by Muscadine Grape Skin Extract and Resveratrol through Distinct Mechanisms.
Cancer Res. 67: 8396-405, 2007.
50)  Kee K, Green J.
Teicher B, eds.
Breast cancer: insights from DNA microarrays. In: Drug Resistance in Malignant Disease.
NJ: Humana Press; 2006. p. 559 - 576 [Book Chapter]
51)  Huh JI, Calvo A, Charles R, Green JE.
Distinct tumor stage-specific inhibitory effects of 2-methoxyestradiol in a breast cancer mouse model associated with Id-1 expression.
Cancer Res. 66: 3495-503, 2006.
52)  Zhang X, Mehta RG, Lantvit DD, Coschigano KT, Kopchick JJ, Green JE, Hedayat S, Christov KT, Ray VH, Unterman TG, Swanson SM.
Inhibition of estrogen independent mammary carcinogenesis by disruption of growth hormone signaling.
Carcinogenesis. 2006.
53)  Oakes SR, Robertson FG, Kench JG, Gardiner-Garden M, Wand MP, Green JE, Ormandy CJ.
Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions.
Oncogene. 2006.
54)  Hsieh CL, Xie Z, Liu ZY, Green JE, Martin WD, Datta MW, Yeung F, Pan D, Chung LW.
A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals.
J. Mol. Endocrinol. 35: 293-304, 2005.
55)  Huang S, Li Y, Chen Y, Podsypanina K, Chamorro M, Olshen AB, Desai KV, Tann A, Petersen D, Green JE, Varmus HE.
Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice.
Genome Biol. 6: R84, 2005.
56)  Wang Z, Prins GS, Coschigano KT, Kopchick JJ, Green JE, Ray VH, Hedayat S, Christov KT, Unterman TG, Swanson SM.
Disruption of Growth Hormone Signaling Retards Early Stages of Prostate Carcinogenesis in the C3(1)/Tag Mouse.
Endocrinology. 2005.
57)  Gonzalez-Moreno O, Calvo A, Joshi BH, Abasolo I, Leland P, Wang Z, Montuenga L, Puri RK, Green JE.
Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin.
Int. J. Cancer. 114: 870-8, 2005.
58)  Huh J, Calvo A, Stafford J, Cheung M, Kumar R, Philp D, Kleinman H, Green J.
Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through anti-angiogenic and non-antiangiogenic mechanisms.
Oncogene. 24: 790 - 800, 2005.
59)  Huh JI, Calvo A, Stafford J, Cheung M, Kumar R, Philp D, Kleinman HK, Green JE.
Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Oncogene. 24: 790-800, 2005.
60)  Gupta V, Carey JL, Kawakubo H, Muzikansky A, Green JE, Donahoe PK, MacLaughlin DT, Maheswaran S.
Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.
Proc Natl Acad Sci U S A. 102: 3219-24, 2005.
61)  Calvo A, Gonzalez-Moreno O, Yoon CY, Huh JI, Desai K, Nguyen QT, Green JE.
Prostate cancer and the genomic revolution: Advances using microarray analyses.
Mutat Res. 576: 66-79, 2005.
62)  Green JE, Hudson T.
The promise of genetically engineered mice for cancer prevention studies.
Nat Rev Cancer. 5: 184-98, 2005.
63)  Petersen D, Chandramouli GV, Geoghegan J, Hilburn J, Paarlberg J, Kim CH, Munroe D, Gangi L, Han J, Puri R, Staudt L, Weinstein J, Barrett JC, Green J, Kawasaki ES.
Three microarray platforms: an analysis of their concordance in profiling gene expression.
BMC Genomics. 6: 63, 2005.
64)  Lubet R, Green J, Steele V, You M.
potential use of transgenic mice in chemoprevention studies. In: Cancer Chemoprevention.
NJ: Humana Press; 2004. p. 47-56 [Book Chapter]
65)  Barkan D, Montagna C, Ried T, Green JE.
Holland E, eds.
Mammary Gland Cancer. In: Mouse Models of Human Cancer.
NY: Wiley; 2004. p. 103-131 [Book Chapter]
66)  Green JE, Desai KV, Ye Y, Kavanaugh C, Calvo A, Huh JI.
Application of gene expression profiling for validating models of human breast cancer.
Toxicol Pathol. 32 Suppl 1: 84-9, 2004.
67)  Shih JH, Michalowska AM, Dobbin K, Ye Y, Qiu TH, Green JE.
Effects of pooling mRNA in microarray class comparisons.
Bioinformatics. 2004.
68)  Kawakubo H, Carey JL, Brachtel E, Gupta V, Green JE, Walden PD, Maheswaran S.
Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer.
Oncogene. 23: 8310-9, 2004.
69)  Kawakubo H, Carey JL, Brachtel E, Gupta V, Green JE, Walden PD, Maheswaran S.
Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer.
Oncogene. 2004.
70)  Desai KV, Michalowska AM, Kondaiah P, Ward JM, Shih JH, Green JE.
Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN (phosphatase and tensin homolog deleted on chromosome 10)-mediated apoptotic response specific to the rat ventral prostate.
Mol Endocrinol. 18: 2895-907, 2004.
71)  Desai KV, Michalowska AM, Kondaiah P, Ward JM, Shih JH, Green JE.
Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN-mediated apoptotic response specific to the rat ventral prostate.
Mol Endocrinol. 2004.
72)  Green JE, eds.
Genomic Approaches to the Study of Breast Cancer.
Breast Disease. 19: 1-91, 2004.
[Journal (Editor)]
73)  Green JE, Desai K, Ye Y, Kavanaugh C, Calvo A, Huh JI.
Genomic approaches to understanding mammary tumor progression in transgenic mice and responses to therapy.
Clin Cancer Res. 10: 385S-90S, 2004.
74)  Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE, Liu ET.
Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease.
Cancer Res. 64: 5973-81, 2004.
75)  Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE, Liu ET.
Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease.
Cancer Res. 64: 5973-81, 2004.
76)  Utomo A, Jiang X, Furuta S, Yun J, Levin DS, Wang YC, Desai KV, Green JE, Chen PL, Lee WH.
Identification of a Novel Putative Non-selenocysteine Containing Phospholipid Hydroperoxide Glutathione Peroxidase (NPGPx) Essential for Alleviating Oxidative Stress Generated from Polyunsaturated Fatty Acids in Breast Cancer Cells.
J Biol Chem. 279: 43522-9, 2004.
77)  Utomo A, Jiang X, Furuta S, Yun J, Levin DS, Wang YC, Desai KV, Green JE, Chen PL, Lee WH.
Identification of a novel putative non-selenocysteine containing phospholipid hydroperoxide glutathione peroxidase (NPGPx) essential for alleviating oxidative stress generated from polyunsaturated fatty acids in breast cancer cells.
J Biol Chem. 279: 43522-9, 2004.
78)  Ye Y, Qiu TH, Kavanaugh C, Green JE.
Molecular mechanisms of breast cancer progression: lessons from mouse mammary cancer models and gene expression profiling.
Breast Dis. 19: 69-82, 2004.
79)  Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS.
Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
Clin Cancer Res. 10: 327S-330S, 2004.
80)  Moody TW, Dudek J, Zakowicz H, Walters J, Jensen RT, Petricoin E, Couldrey C, Green JE.
VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice.
Life Sci. 74: 1345-57, 2004.
81)  Fargiano AA, Desai KV, Green JE.
Interrogating mouse mammary cancer models: insights from gene expression profiling.
J Mammary Gland Biol Neoplasia. 8: 321-34, 2003.
82)  Robertson FG, Harris J, Naylor MJ, Oakes SR, Kindblom J, Dillner K, Wennbo H, Törnell J, Kelly PA, Green J, Ormandy CJ.
Prostate development and carcinogenesis in prolactin receptor knockout mice.
Endocrinology. 144: 3196-205, 2003.
83)  Guo C, Yu S, Davis AT, Wang H, Green JE, Ahmed K.
A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells.
J. Biol. Chem. 276: 5992-9, 2001.
84)  Yu S, Davis AT, Guo C, Green JE, Ahmed K.
Differential targeting of protein kinase CK2 to the nuclear matrix upon transient overexpression of its subunits.
J. Cell. Biochem. 74: 127-34, 1999.
85)  Shibata MA, Liu ML, Knudson MC, Shibata E, Yoshidome K, Bandey T, Korsmeyer SJ, Green JE.
Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage.
EMBO J. 18: 2692-701, 1999.
86)  Maroulakou IG, Shibata MA, Anver M, Jorcyk CL, Liu M, Roche N, Roberts AB, Tsarfaty I, Reseau J, Ward J, Green JE.
Heterotopic endochondrial ossification with mixed tumor formation in C3(1)/Tag transgenic mice is associated with elevated TGF-beta1 and BMP-2 expression.
Oncogene. 18: 5435-47, 1999.
87)  Shibata MA, Jorcyk CL, Devor DE, Yoshidome K, Rulong S, Resau J, Roche N, Roberts AB, Ward JM, Green JE.
Altered expression of transforming growth factor betas during urethral and bulbourethral gland tumor progression in transgenic mice carrying the androgen-responsive C3(1) 5' flanking region fused to SV40 large T antigen.
Carcinogenesis. 19: 195-205, 1998.
88)  Liu ML, Von Lintig FC, Liyanage M, Shibata MA, Jorcyk CL, Ried T, Boss GR, Green JE.
Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice.
Oncogene. 17: 2403-11, 1998.
89)  Jorcyk CL, Liu ML, Shibata MA, Maroulakou IG, Komschlies KL, McPhaul MJ, Resau JH, Green JE.
Development and characterization of a mouse prostate adenocarcinoma cell line: ductal formation determined by extracellular matrix.
Prostate. 34: 10-22, 1998.
90)  Yoshidome K, Shibata MA, Maroulakou IG, Liu ML, Jorcyk CL, Gold LG, Welch VN, Green JE.
Genetic alterations in the development of mammary and prostate cancer in the C3(1)/Tag transgenic mouse model.
Int. J. Oncol. 12: 449-53, 1998.
91)  Shibata MA, Jorcyk CL, Liu ML, Yoshidome K, Gold LG, Green JE.
The C3(1)/SV40 T antigen transgenic mouse model of prostate and mammary cancer.
Toxicol Pathol. 26: 177-82, 1998.
92)  Green JE, Greenberg NM, Ashendel CL, Barrett JC, Boone C, Getzenberg RH, Henkin J, Matusik R, Janus TJ, Scher HI.
Workgroup 3: transgenic and reconstitution models of prostate cancer.
Prostate. 36: 59-63, 1998.
93)  Shibata MA, Ward JM, Green JE, Merlino G.
Enhanced sensitivity to tumor growth and development in multistage skin carcinogenesis by transforming growth factor-alpha-induced epidermal growth factor receptor activation but not p53 inactivation.
Mol. Carcinog. 18: 160-70, 1997.
94)  Jorcyk CL, Garrett LJ, Maroulakou IG, Watson DK, Green JE.
Multiple regulatory regions control the expression of Ets-1 in the developing mouse: vascular expression conferred by intron I.
Cell. Mol. Biol. (Noisy-le-grand). 43: 211-25, 1997.
95)  Maroulakou IG, Shibata MA, Jorcyk CL, Chen XX, Green JE.
Reduced p53 dosage associated with mammary tumor metastases in C3(1)/TAG transgenic mice.
Mol. Carcinog. 20: 168-74, 1997.
96)  Wigginton JM, Komschlies KL, Green JE, Cox GW, Jorcyk CL, Back TC, Franco JL, Brunda MJ, Wiltrout RH.
Evaluation of the antitumor activity of the interleukin-12/pulse interleukin-2 combination.
Ann. N. Y. Acad. Sci. 795: 434-9, 1996.
97)  Ritchie GY, Mungthin M, Green JE, Bray PG, Hawley SR, Ward SA.
In vitro selection of halofantrine resistance in Plasmodium falciparum is not associated with increased expression of Pgh1.
Mol. Biochem. Parasitol. 83: 35-46, 1996.
98)  Chen SL, Maroulakou IG, Green JE, Romano-Spica V, Modi W, Lautenberger J, Bhat NK.
Isolation and characterization of a novel gene expressed in multiple cancers.
Oncogene. 12: 741-51, 1996.
99)  Shibata MA, Maroulakou IG, Jorcyk CL, Gold LG, Ward JM, Green JE.
p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma.
Cancer Res. 56: 2998-3003, 1996.
100)  Shibata MA, Ward JM, Devor DE, Liu ML, Green JE.
Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations.
Cancer Res. 56: 4894-903, 1996.
101)  Byeon MK, Westerman MA, Maroulakou IG, Henderson KW, Suster S, Zhang XK, Papas TS, Vesely J, Willingham MC, Green JE, Schweinfest CW.
The down-regulated in adenoma (DRA) gene encodes an intestine-specific membrane glycoprotein.
Oncogene. 12: 387-96, 1996.
102)  Peebles RS, Maliszewski CR, Sato TA, Hanley-Hyde J, Maroulakou IG, Hunziker R, Schneck JP, Green JE.
Abnormal B-cell function in HTLV-I-tax transgenic mice.
Oncogene. 10: 1045-51, 1995.
103)  Pokholok DK, Maroulakou IG, Kuprash DV, Alimzhanov MB, Kozlov SV, Novobrantseva TI, Turetskaya RL, Green JE, Nedospasov SA.
Cloning and expression analysis of the murine lymphotoxin beta gene.
Proc. Natl. Acad. Sci. U.S.A. 92: 674-8, 1995.
104)  Maroulakou IG, Papas TS, Green JE.
Differential expression of ets-1 and ets-2 proto-oncogenes during murine embryogenesis.
Oncogene. 9: 1551-65, 1994.
105)  Maroulakou IG, Anver M, Garrett L, Green JE.
Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene.
Proc. Natl. Acad. Sci. U.S.A. 91: 11236-40, 1994.
106)  Green JE, Baird AM, Hinrichs SH, Klintworth GK, Jay G.
Adrenal medullary tumors and iris proliferation in a transgenic mouse model of neurofibromatosis.
Am. J. Pathol. 140: 1401-10, 1992.
107)  Green JE.
trans activation of nerve growth factor in transgenic mice containing the human T-cell lymphotropic virus type I tax gene.
Mol. Cell. Biol. 11: 4635-41, 1991.
108)  Green JE, Adams GW, Shawker TH, Sax FL, Koeller DM, Zasloff MA.
Hypertension and renal failure in a patient with tuberous sclerosis.
South. Med. J. 83: 451-4, 1990.
109)  Green JE, Hinrichs SH, Vogel J, Jay G.
Exocrinopathy resembling Sjögren's syndrome in HTLV-1 tax transgenic mice.
Nature. 341: 72-4, 1989.
110)  Bale SJ, Bale AE, Stewart K, Dachowski L, McBride OW, Glaser T, Green JE, Mulvihill JJ, Brandi ML, Sakaguchi K.
Linkage analysis of multiple endocrine neoplasia type 1 with INT2 and other markers on chromosome 11.
Genomics. 4: 320-2, 1989.
111)  Green JE, Begley CG, Wagner DK, Waldmann TA, Jay G.
trans activation of granulocyte-macrophage colony-stimulating factor and the interleukin-2 receptor in transgenic mice carrying the human T-lymphotropic virus type 1 tax gene.
Mol. Cell. Biol. 9: 4731-7, 1989.
112)  Green JE, Rosenbaum KN, Rapoport SI, Schapiro MB, White BJ.
Variant nucleolus organizing regions and the risk of Down syndrome.
Clin. Genet. 35: 243-50, 1989.
113)  Green JE, Dorfmann A, Jones SL, Bender S, Patton L, Schulman JD.
Chorionic villus sampling: experience with an initial 940 cases.
Obstet Gynecol. 71: 208-12, 1988.
114)  Green JE.
Abdominal mass in the neonate.
Pediatr Emerg Care. 1: 28-31, 1985.
115)  Green JE, McLean F, Smith LP, Usher R.
Has an increased cesarean section rate for term breech delivery reduced in incidence of birth asphyxia, trauma, and death?.
Am. J. Obstet. Gynecol. 142: 643-8, 1982.
116)  Gonzales-Moreno O, Calvo A, Joshi BH, Abasolo I, Wang A, Montuenga L, Puri RK, Green JE.
Gene expression profiling identifities IL-3 receptor alpha2 chani as a therapeutic target in prostate tumor cells over-expression adrenomedullin.
Int. J. Cancer. in press, .
117)  Desai KV, Xiao N, Wang W, Gangi L, Greene J, Powell JI, Dickson R, Furth P, Hunter K, Kucherlapati R, Simon R, Liu ET, Green JE.
Initiating oncogenic event determines gene-expression patterns of human breast cancer models.
Proc Natl Acad Sci U S A. 99: 6967-72, 2002.
118)  Green JE, Shibata MA, Shibata E, Moon RC, Anver MR, Kelloff G, Lubet R.
2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Cancer Res. 61: 7449-55, 2001.
119)  Calvo A, Feldman AL, Libutti SK, Green JE.
Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3(1)/SV40 T-antigen transgenic mice.
Cancer Res. 62: 3934-8, 2002.
120)  Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, Jorcyk C, Green JE.
Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
Cancer Res. 62: 5325-35, 2002.
121)  Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB, Green JE.
Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models.
Carcinogenesis. 24: 453-9, 2003.
122)  Holzer RG, MacDougall C, Cortright G, Atwood K, Green JE, Jorcyk CL.
Development and characterization of a progressive series of mammary adenocarcinoma cell lines derived from the C3(1)/SV40 Large T-antigen transgenic mouse model.
Breast Cancer Res Treat. 77: 65-76, 2003.
123)  Kaczmarczyk SJ, Green JE.
Induction of cre recombinase activity using modified androgen receptor ligand binding domains: a sensitive assay for ligand-receptor interactions.
Nucleic Acids Res. 31: e86, 2003.
124)  Best CJ, Leiva IM, Chuaqui RF, Gillespie JW, Duray PH, Murgai M, Zhao Y, Simon R, Kang JJ, Green JE, Bostwick DG, Linehan WM, Emmert-Buck MR.
Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis.
Diagn Mol Pathol. 12: 63-70, 2003.
125)  Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, LeRoith D, Yakar S.
Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors.
Cancer Res. 63: 4384-8, 2003.
126)  Kavanaugh C, Green JE.
The use of genetically altered mice for breast cancer prevention studies.
J Nutr. 133: 2404S-2409S, 2003.
127)  Desai KV, Kavanaugh CJ, Calvo A, Green JE.
Chipping away at breast cancer: insights from microarray studies of human and mouse mammary cancer.
Endocr Relat Cancer. 9: 207-20, 2002.
128)  Desai KV, Kavanaugh CJ, Calvo A, Green JE.
Chipping away at breast cancer: insights from microarray studies of human and mouse mammary cancer.
Endocr Relat Cancer. 9: 207-20, 2002.
129)  Soares CR, Shibata MA, Green JE, Jorcyk CL.
Development of PIN and prostate adenocarcinoma cell lines: a model system for multistage tumor progression.
Neoplasia. 4: 112-20, 2002.
130)  Calvo A, Yokoyama Y, Smith LE, Ali I, Shih SC, Feldman AL, Libutti SK, Sundaram R, Green JE.
Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin.
Int J Cancer. 101: 224-34, 2002.
131)  Shih SC, Robinson GS, Perruzzi CA, Calvo A, Desai K, Green JE, Ali IU, Smith LE, Senger DR.
Molecular profiling of angiogenesis markers.
Am J Pathol. 161: 35-41, 2002.
132)  Kavanaugh CJ, Desai KV, Calvo A, Brown PH, Couldrey C, Lubet R, Green JE.
Pre-clinical applications of transgenic mouse mammary cancer models.
Transgenic Res. 11: 617-33, 2002.
133)  Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH.
Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
Cancer Epidemiol Biomarkers Prev. 11: 467-74, 2002.
134)  Green JE, Cardiff R, Hennighausen L, Wakefield L, Wagner U, Lee E, Rosen J, Medina D, Nitkin A, Liu E.
Validation of transgenic mammary cancer models: goals of the NCI Mouse Models of Human Cancer Consortium and the mammary cancer CD-ROM.
Transgenic Res. 11: 635-6, 2002.
135)  Wubah JA, Fischer CM, Rolfzen LN, Khalili M, Kang J, Green JE, Bieberich CJ.
Ventral prostate predominant l, a novel mouse gene expressed exclusively in the prostate.
Prostate. 51: 21-9, 2002.
136)  Kaczmarczyk SJ, Green JE.
A single vector containing modified cre recombinase and LOX recombination sequences for inducible tissue-specific amplification of gene expression.
Nucleic Acids Res. 29: E56-6, 2001.
137)  Wigginton JM, Park JW, Gruys ME, Young HA, Jorcyk CL, Back TC, Brunda MJ, Strieter RM, Ward J, Green JE, Wiltrout RH.
Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis.
J Immunol. 166: 1156-68, 2001.
138)  Liu ML, Shibata MA, Von Lintig FC, Wang W, Cassenaer S, Boss GR, Green JE.
Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice.
Oncogene. 20: 2044-9, 2001.
139)  Shibata MA, Yoshidome K, Shibata E, Jorcyk CL, Green JE.
Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21.
Cancer Gene Ther. 8: 23-35, 2001.
140)  Wu K, Kim HT, Rodriquez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, Lamph WW, Gottardis MM, Shirley MA, Kuhn JG, Green JE, Brown PH.
9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice.
Clin Cancer Res. 6: 3696-704, 2000.
141)  Yokoyama Y, Green JE, Sukhatme VP, Ramakrishnan S.
Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model.
Cancer Res. 60: 4362-5, 2000.
142)  Yoshidome K, Shibata MA, Couldrey C, Korach KS, Green JE.
Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression.
Cancer Res. 60: 6901-10, 2000.
143)  Hahm KB, Im YH, Lee C, Parks WT, Bang YJ, Green JE, Kim SJ.
Loss of TGF-beta signaling contributes to autoimmune pancreatitis.
J Clin Invest. 105: 1057-65, 2000.
144)  Couldrey C, Green JE.
Metastases: the glycan connection.
Breast Cancer Res. 2: 321-3, 2000.
145)  Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, Wang W, Liu ZY, Calvo A, Couldrey C.
The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.
Oncogene. 19: 1020-7, 2000.
146)  Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE.
The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting.
Oncogene. 19: 968-88, 2000.
Click Here to View Collapsed Bibliography.

This page was last updated on 9/16/2013.